Bluesight vs Imprivata Patient Privacy Intelligence (2026)
Both monitor staff access to patient records with machine learning. Bluesight's PrivacyPro, the former Protenus platform, scores accesses and groups suspicious ones into cases. Bluesight also sells drug diversion monitoring and a pharmacy suite. Imprivata PPI, formed from the FairWarning and Maize Analytics products, watches access across the record system and other applications. Explanation based auditing ties each access to a reason, such as an encounter or appointment, and surfaces what it cannot explain. Behavioral baselines and machine learning score the risk of what remains, and Imprivata's managed privacy service can run it. Choose Bluesight for case scoring alongside a pharmacy suite; choose Imprivata PPI for access explained against clinical reasons and a published business associate agreement.
- Suspicious accesses should be scored and grouped into cases for investigators.
- Pharmacy wants 340B, drug spend and kit inventory tools from the same vendor.
- You are moving from Protenus and want to stay on its platform.
- Each access should be tied to a clinical reason before anything is flagged.
- You run Imprivata access management and want privacy monitoring alongside it.
- A published business associate agreement and named certifications should be in hand before a sales call.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Bluesight and Imprivata Patient Privacy Intelligence are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Bluesight | Imprivata Patient Privacy Intelligence |
|---|---|---|
| Primary category | Healthcare Cybersecurity | Healthcare Cybersecurity |
| Founded | 2011 | Not recorded |
| Headquarters | Alexandria, Virginia, United States | Waltham, Massachusetts, United States |
| Website | bluesight.com | imprivata.com |
Side by Side
Select any grade to read the note behind it.
Product updates
The latest logged changes from each vendor, newest first, each linked to its source.
Imprivata Patient Privacy Intelligence
-
Product / capability
Release 26.11 of Imprivata Access Intelligence extends the AI alert summarizer that Patient Privacy Intelligence gained in 26.10.
Source
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Bluesight sells medication and compliance software to hospital pharmacies, and two of its products watch hospital staff for insider risk. ControlCheck, formerly Bluesight for Controlled Substances, detects drug diversion. PrivacyPro, the former Protenus platform, flags inappropriate access to patient records.
Source: AI Health Index, September 2026
Imprivata Patient Privacy Intelligence (PPI) watches who opens patient records and flags access that has no clinical or business reason. Hospital and health system privacy officers, security teams and compliance staff buy it for proactive monitoring and for investigating complaints.
Source: AI Health Index, September 2026
Questions buyers ask
How are Bluesight and Imprivata Patient Privacy Intelligence priced and sold?
Bluesight publishes no price, unit, pricing basis, contract shape or implementation fee for ControlCheck; the one structural detail on the product page is that it offers unlimited user seats, which says what does not drive the cost without saying what does.
The Access Intelligence Platform appendix to Imprivata's Master License and Services Agreement says a base subscription covers one Imprivata data source with unlimited storage and is priced on the number of unique user IDs in that source, with fees rising by the same percentage if the count grows during the term and a 30 day window to dispute the recount. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 30, 2026. No vendor pays for placement.
Which settings and specialties do Bluesight and Imprivata Patient Privacy Intelligence cover?
In Bluesight's case, coverage is deep across two insider risk domains and the pharmacy operations around them. ControlCheck covers the controlled substance custody path from wholesaler and vault through dispense, administration, waste and return, across procedural areas, nursing, inpatient pharmacy and, through ControlCheck Retail, retail pharmacy.
For Imprivata Patient Privacy Intelligence, no setting beyond hospitals and health systems, such as clinics or physician groups, is shown running it. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 30, 2026. No vendor pays for placement.
What evidence is published for Bluesight and Imprivata Patient Privacy Intelligence?
For ControlCheck, Bluesight reports more than 2,200 confirmed diversion cases, more than 47,000 potential cases investigated and closed, and at UCSF Health automatic reconciliation of 95 percent of controlled substance vault transactions with a 74 percent cut in the time taken.
In Imprivata Patient Privacy Intelligence's case, the explanation based approach PPI inherits from Maize Analytics comes from Daniel Fabbri and Kristen LeFevre's "Explanation-Based Auditing" (Proceedings of the VLDB Endowment, volume 5, 2012), which explained over 94 percent of accesses in a University of Michigan Health System access log; Fabbri founded Maize. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 30, 2026. No vendor pays for placement.
How much do Bluesight and Imprivata Patient Privacy Intelligence leave to the clinician?
Prism Assistant drafts investigation notes and escalation emails for the investigator, and Bluesight says Prism's connected agents will proactively monitor and flag activity across its applications.
Imprivata's Responsible AI Transparency Report says its models "are not intended to replace human decision-making", that products require "the customer to configure their risk tolerance and ultimately make any decisions regarding the anomalies identified", and that "The AI requires human oversight and feedback to take action". From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 30, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Healthcare Cybersecurity page.
Neither publishes a price. Imprivata prices by the user IDs counted in each monitored data source, with no rate published. Imprivata publishes a business associate agreement covering every customer. Bluesight claims HIPAA compliance but publishes no agreement. Imprivata's datasheet says PPI reviews 99 percent of the access log and presents the remaining 1 percent. It gives no method for that figure. No check on what is cleared automatically is stated. Imprivata describes a single tenant hosted environment for PPI's product family and names Amazon Web Services as its hosting subprocessor, but does not publish where PPI's data rests or which record systems it connects to. Its Responsible AI Transparency Report sets out a framework without PPI results.
Ask Imprivata how the automatically cleared accesses are checked, and ask Bluesight how PrivacyPro's case scores are validated.